$37.510
+0.488 (+1.30%)At close
HRMY News
HRMY Events
Harmony Biosciences Appoints Peter Anastasiou as CEO
After Harmony Biosciences announced that Peter Anastasiou, the company's current COO, will become President, CEO and a board member, Mizuho analyst Graig Suvannavejh said the news "comes as no major surprise to us" and adds that the firm has been of the view "that it was more a question of when, not if, he would take over as HRMY's next CEO." The firm, which is positive on Anastasiou and also the CEO transition, keeps an Outperform rating on Harmony shares.
Harmony Biosciences Appoints Peter Anastasiou as New CEO
Harmony Biosciences announced that, as part of the board of directors' succession planning, Peter Anastasiou, former Harmony board member and current EVP and COO, has been appointed president, CEO and member of the board of directors, effective January 1, 2027. He succeeds Jeffrey Dayno, who will retire as president and CEO and step down from the board of directors on December 31. To support the leadership transition, Dayno will serve as a non-executive advisor to the company throughout 2027 to support Harmony's growth objectives.
Harmony Biosciences Reports Q2 Revenue of $261.28M
Reports Q2 revenue $261.28M, consensus $253.27M. "Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders," said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. "The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications."
Harmony Biosciences Expects Full-Year Net Revenue of $1.0 to $1.04 Billion
"Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."
Harmony Reiterates 2026 Net Product Revenue Guidance of $1.0 to $1.04 Billion
Based on its first-half performance and current business trends, Harmony is reiterating its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.